KalVista Pharmaceuticals announced an FDA delay in the decision on approval of its oral on-demand treatment for hereditary angioedema, attributing the postponement to agency workload and limited resources. This unexpected delay affects KalVista's development plans for the drug expected to expand treatment options for this rare genetic condition characterized by acute swelling attacks.